Lipoprotein(a) and Cardiovascular Disease: A Review of Current Evidence and Future Directions
Keywords:
Lipoprotein(a), low-density lipoprotein (LDL), Oxidized phospholipids (OxPL), Atherosclerotic cardiovascular disease (ASCVD), Calcific aortic valve stenosis (CAV)Abstract
Lipoprotein(a), Lp(a), is a type of low-density lipoprotein (LDL) that is now widely understood to be an independent and direct risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS). Plasma Lp(a) levels are predominantly (over 90%) genetically determined, making them relatively stable throughout life and unresponsive to lifestyle modifications or most currently available lipid-lowering therapies. The pathophysiology of Lp(a) is complex, involving pro-atherogenic, pro-inflammatory, and pro-thrombotic mechanisms, primarily driven by its unique protein component, apolipoprotein (a) (apo(a)), and its role as the primary carrier of oxidized phospholipids (OxPL). Despite challenges in measurement standardization, a global clinical consensus is emerging, recommending at least a one-time screening for Lp(a) in all adults. The field is on the cusp of a major therapeutic breakthrough with the development of specific Lp(a)-lowering RNA-based therapies, such as pelacarsen and olpasiran, as well as a novel oral agent, muvalaplin, which are in late-stage trials and promise to address this long-recognized risk factor for the first time.
References
Berg K. A new serum type system in man--the Lp system. Acta Pathol Microbiol Scand. 1963; 59: 369-82. https://doi.org/10.1111/j.1699-0463.1963.tb01808.x
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022; 43 (39): 3925-47. https://doi.org/10.1093/eurheartj/ehac361
Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016; 57 (4): 526-37. https://doi.org/10.1194/jlr.R061648
Capoulade R, Yeang C, Chan KL, et al. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: A Substudy of the ASTRONOMER Trial. JAMA Cardiol. 2018; 3 (12): 1212-7. https://doi.org/10.1001/jamacardio.2018.3798
Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302 (4): 412-23. https://doi.org/10.1001/jama.2009.1063
Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361 (26): 2518-28. https://doi.org/10.1056/NEJMoa0902604
McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature. 1987; 330 (6144): 132-7. https://doi.org/10.1038/330132a0
Boffa MB, Koschinsky ML. Lipoprotein (a) and cardiovascular disease. Biochem J. 2024; 481 (19):1277-96. https://doi.org/10.1042/BCJ20240037
Utermann G. The mysteries of lipoprotein (a). Science. 1989; 246 (4932): 904-10. https://doi.org/10.1126/science.2530631
Kraft HG, Lingenhel A, Köchl S, et al. Apolipoprotein (a) Kringle IV-2 copy number is a major determinant of plasma lipoprotein(a). Hum Mol Genet. 1996; 5 (10):1599-606.
White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem. 1994; 269 (46): 28716-23. https://doi.org/10.1016/S0021-9258(19)61964-2
Boffa MB, Koschinsky ML. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism. 2013; 62 (4): 479-91. https://doi.org/10.1016/j.metabol.2012.07.024
Tsimikas S, Hall JL. Lipoprotein (a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease: A Rationale for Increased Efforts to Understand its Pathophysiology and Develop Targeted Therapies. JACC. 2012; 60 (8): 716-21. https://doi.org/10.1016/j.jacc.2012.04.038
Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol. 2016; 13 (1): 35-46.
Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating the pro-inflammatory and proatherogenic effects of lipoprotein (a). J Lipid Res. 2008; 49 (8):1697-711.
Burkhardt R. Hyperlipidemia and cardiovascular disease: new insights on lipoprotein(a). Curr Opin Lipidol. 2019; 30 (3): 260-1. https://doi.org/10.1097/MOL.0000000000000594
Cai A, Li L, Li S, et al. Lipoprotein(a) and the risk of premature atherosclerotic cardiovascular disease: a systematic review and meta-analysis. EHJ Open. 2024; 4 (3): oeae031. https://doi.org/10.1093/ehjopen/oeae031
Paré G, Çaku A, McQueen M, et al. Lipoprotein(a) levels and the risk of myocardial infarction, ischemic stroke, and peripheral arterial disease: a Mendelian randomization analysis. Circ Cardiovasc Genet. 2013; 6 (3): 233-40.
Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013; 368 (6): 503-12. https://doi.org/10.1056/NEJMoa1109034
Capoulade R, Chan KL, Yeang C, et al. Causal association of lipoprotein(a) with aortic valve calcification and clinical aortic stenosis. Arterioscler Thromb Vasc Biol. 2015; 35 (8):1849-55.
Arsenault BJ, Boekholdt SM, Dubé MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014; 7 (3): 304-10. https://doi.org/10.1161/CIRCGENETICS.113.000400
Bourgeois R, Gencer B, L'Allier PL, et al. Lipoprotein(a) and the risk of aortic stenosis progression. J Am Coll Cardiol. 2020; 75 (25): 3103-12.
Mathieu P, Boulanger MC, Bouchareb R, et al. Lipoprotein(a) and calcific aortic valve stenosis: a systematic review. Can J Cardiol. 2017; 33 (10): 1314-21.
Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol. 1998; 82 (12A): 57U-66U. https://doi.org/10.1016/S0002-9149(98)00954-0
Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016; 57 (4): 526-37. https://doi.org/10.1194/jlr.R061648
Kotani K.The Importance of the Harmonization and Standardization of Lipoprotein(a) Measurements. J Atheros and Thromb. 2025; 32 (5). https://doi.org/10.5551/jat.ED279
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111-88. https://doi.org/10.1093/eurheartj/ehz455
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ ABC/ACPM/ADA/AGS/APhA/ ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019; 73 (24): e285-e350. https://doi.org/10.1016/j.jacc.2018.11.003
Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021; 37 (8): 1129-50. https://doi.org/10.1016/j.cjca.2021.03.016
Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis. 2019; 291: 62-70. https://doi.org/10.1016/j.atherosclerosis.2019.10.011
Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019; 13 (3): 374-92. https://doi.org/10.1016/j.jacl.2019.04.010
Tsimikas S, et al. Statins increase lipoprotein (a) levels. Eur Heart J. 2020; 41(24): 2275-84. https://doi.org/10.1093/eurheartj/ehz310
Sahebkar A, Simental-Mendía LE, Pirro M, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations: Systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018; 8 (1): 17829. https://doi.org/10.1038/s41598-018-36204-7
Boden WE, Sidhu MS, Toth PP. The Therapeutic Role of Niacin in Dyslipidemia Management. J Cardiovas Pharmacol Therapeu. 2014; 19 (2): 141-58. https://doi.org/10.1177/1074248413514481
AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365 (24): 2255-67. https://doi.org/10.1056/NEJMoa1107579
Ruscica M, Greco MF, Ferri N, Corsini A. Lipoprotein (a) and PCSK9 inhibition: clinical evidences. Eur Heart J Suppl. 2020; 22 (Suppl L): L53-L56. https://doi.org/10.1093/eurheartj/suaa135
O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019; 139 (12): 1483-92. https://doi.org/10.1161/CIRCULATIONAHA.118.037184 3
Thompson G. Lipoprotein apheresis. Curr Opin Lipidol. 2010; 21 (6): 487-91. https://doi.org/10.1097/MOL.0b013e32833e13fd
Tsimikas S, Viney NJ, Hughes SG, et al. Antisense inhibition of apolipoprotein (a) to lower lipoprotein(a) concentrations in humans. Lancet. 2015; 386 (10002): 1472-83. https://doi.org/10.1016/S0140-6736(15)61252-1
Bhatia HS, Bajaj A, Goonewardena SN, Moriarty PM. Pelacarsen: Mechanism of action and Lp(a)- lowering effect. J Clin Lipidol. 2025; 19 (5): 1208-22. https://doi.org/10.1016/j.jacl.2025.06.004
Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein (a) in people with raised lipoprotein(a): two randomised, double-masked, placebo-controlled, dose-ranging trials. Lancet. 2016; 388 (10057): 2239-53. https://doi.org/10.1016/S0140-6736(16)31009-1
O'Donoghue ML, Rosenson RS, Gencer B, López JAG. Lepor NE, Baum SJ, et al. for the OCEAN (a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein (a) in Cardiovascular Disease. N Engl J Med. 2022; 387 (20): 1855-64. https://doi.org/10.1056/NEJMoa2211023
O'Donoghue ML, Rosenson RS, López JAG, Lepor NE, Baum SJ, Elmer Stout E, et al. The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN (a)-DOSE Extension Period Results. J Am Coll Cardiol. 2024; 84 (9): 790-7. https://doi.org/10.1016/j.jacc.2024.05.058
Nicholls SJ, Nissen SE, Fleming C, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA. 2023; 330 (11):1042-53. https://doi.org/10.1001/jama.2023.16503
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020; 41 (24): 2275-84. https://doi.org/10.1093/eurheartj/ehz310
O'Donoghue ML, López JAG, Knusel B, Gencer B, Wang H, Wuet Y, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoprotein(a) reduction- DOSE finding study (OCEAN(a)- DOSE). Am Heart J. 2022; 251: 61-69. https://doi.org/10.1016/j.ahj.2022.05.004
Rosenson RS, López JAG, Gaudet D, Baum SJ, Stout E, Lepor NE, et al. Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial. JAMA Cardiol. 2025; 10 (5): 482-6. https://doi.org/10.1001/jamacardio.2024.5433
Nicholls SJ, Nissen SE, Fleming C, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA. 2023; 330 (11): 1042-53. https://doi.org/10.1001/jama.2023.16503
Novartis. A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease (Lp(a)HORIZON). ClinicalTrials.gov Identifier: NCT0 4023552.
Amgen. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) (OCEAN (a) Outcomes). ClinicalTrials.gov Identifier: NCT0 5581303.
Amgen. Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN (a)) - Outcomes Trial. Available at: https://www.amgentrials.com/study/?id=20180244. Accessed July 13, 2025.
Tsimikas S. Lipoprotein (a) in the Year 2024: A Look Back and a Look Ahead. Arterio Thrombos, Vasc Biol. 2024; 44 (7): 1485-90. https://doi.org/10.1161/ATVBAHA.124.319483
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Greater Mekong Subregion Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
